StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$18.60+0.25 (+1.36%)

Close on Nov 13, 2026Market cap $102.18MP/E –Yield –

InMed Pharmaceuticals profit margin

Profit margin (net margin) is net income as a percentage of revenue.

InMed Pharmaceuticals's profit margin for the twelve months ending Dec 31, 2025 was -26.7%. For fiscal 2025 it was -34.4%, against -166.9% the year before. The highest annual figure on record is -34.4% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Jun 30, 2025-34.4%+132.5
FY2024Jun 30, 2024-166.9%+25.2
FY2023Jun 30, 2023-192.2%+1515.1
FY2022Jun 30, 2022-1707.3%−1171.4
FY2021Jun 30, 2021-535.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ4 2025Dec 31, 2025-247.3%−15.7
Q1 FY2026CQ3 2025Sep 30, 2025-154.2%−21.5
Q4 FY2025CQ2 2025Jun 30, 2025358.2%+509.2
Q3 FY2025CQ1 2025Mar 31, 2025-168.1%−21.2
Q2 FY2025CQ4 2024Dec 31, 2024-231.6%−112.4
Q1 FY2025CQ3 2024Sep 30, 2024-132.7%+148.6
Q4 FY2024CQ2 2024Jun 30, 2024-151.0%−136.4
Q3 FY2024CQ1 2024Mar 31, 2024-146.9%+46.3
Q2 FY2024CQ4 2023Dec 31, 2023-119.2%+328.1
Q1 FY2024CQ3 2023Sep 30, 2023-281.3%+813.0
Q4 FY2023CQ2 2023Jun 30, 2023-14.6%+1514.2
Q3 FY2023CQ1 2023Mar 31, 2023-193.2%+929.4
Q2 FY2023CQ4 2022Dec 31, 2022-447.2%+1168.3
Q1 FY2023CQ3 2022Sep 30, 2022-1094.2%−724.2
Q4 FY2022CQ2 2022Jun 30, 2022-1528.9%−819.7
Q3 FY2022CQ1 2022Mar 31, 2022-1122.7%−312.0
Q2 FY2022CQ4 2021Dec 31, 2021-1615.6%–
Q4 FY2021CQ2 2021Jun 30, 2021-370.0%–
Q3 FY2021CQ1 2021Mar 31, 2021-709.2%–
Q2 FY2021CQ4 2020Dec 31, 2020-810.6%–

More InMed Pharmaceuticals figures

See a number that looks wrong?